# A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)

> **NCT06519682** · NA · RECRUITING · sponsor: **Daniel Morgenstern** · enrollment: 20 (estimated)

## Conditions studied

- High Grade Glioma
- Replication Repair Deficient

## Interventions

- **DRUG:** Nivolumab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT06519682
- **Lead sponsor:** Daniel Morgenstern
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-06
- **Primary completion:** 2026-12
- **Final completion:** 2029-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519682, "A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06519682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*